Science - Biotechnologies latest news

TORONTO, ONTARIO (MARKET WIRE) PharmEng International Inc. ("PharmEng") (TSX VENTURE: PII), today announced that its wholly owned subsidiary, Keata Pharma Inc. ("Keata"), received a drug establishment license on June 26, 2008 for its manufacturing facility located in Sydney, Nova Scotia. The establishment license was issued after a Good Manufacturing Practices (GMP) inspection was conducted under the authority of the Food and Drugs Act to verify compliance with the applicable regulations. The inspection concluded favourably on June 13,2008. The establishment license is for the manufacturing, testing and packaging of the

NANTES, FRANCE and CAMBRIDGE, MA (MARKET WIRE) VIVALIS GRANTS RESEARCH LICENCE TO ACAMBIS

Former Senate Majority Leader Joseph Bruno says he won't finish out his term. (GE)

Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration has accepted for review the company's new drug application for Ampligen, an experimental chronic fatigue syndrome treatment.

Conceptual MindWorks Inc. (CMI) will host Nobel Laureate biochemist Kary Banks Mullis at a technical exchange luncheon at its headquarters in San Antonio on July 10th.

Monogram Biosciences Inc. said Tuesday that it will make its HERmark breast cancer assay available to doctors throughout the United States starting July 15. (MGRM) (IVGN)

Johnson & Johnson said Tuesday it is moving about 260 positions from its Ortho Biotech unit to Centocor in Horsham, Pa. (JNJ)

Biotechnology company Arca Biopharma Inc. moved its headquarters from Denver to a new building next to the Broomfield Event Center on U.S. 36, the company announced Tuesday.

ANN ARBOR, MI (MARKET WIRE) Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous systems and autoimmune diseases, today announced that it will hold a conference call on Wednesday, July 9, 2008 at 10:15 a.m. ET to discuss the results of its double-blind, placebo-controlled phase II clinical trial results in the treatment of dry age-related macular degeneration (AMD) with oral Z-Monocys. Nicholas Stergis, Vice Chairman and Chief Executive Officer of Pipex, will host the call.

MISSISSAUGA, ONTARIO (MARKET WIRE) Covalon Technologies Ltd. (TSX VENTURE: COV) is pleased to announce that it has reached a significant milestone in its research as part of a Development Agreement with one of the world's largest vascular access device companies.